Case Report: MSS colorectal extrahepatic (non-liver) metastases as the dominant population for immunotherapy combined with multi-target tyrosine kinase inhibitors
BackgroundThe microsatellite stability(MSS) subtype of Colorectal Cancer(CRC) represents approximately 95% of mCRC cases. Immunotherapy was not as encouraging as the data for MSS mCRC cancer. We report the treatment of a series of patients with extrahepatic metastasis of MSS colorectal cancer, which...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-03-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1091669/full |
| _version_ | 1811155408986832896 |
|---|---|
| author | Jiayin Liu Dan Li Jing Han Yin Zhang Xue Zhang Zhisong Fan Li Feng Long Wang Hui Jin Jing Zuo Yudong Wang |
| author_facet | Jiayin Liu Dan Li Jing Han Yin Zhang Xue Zhang Zhisong Fan Li Feng Long Wang Hui Jin Jing Zuo Yudong Wang |
| author_sort | Jiayin Liu |
| collection | DOAJ |
| description | BackgroundThe microsatellite stability(MSS) subtype of Colorectal Cancer(CRC) represents approximately 95% of mCRC cases. Immunotherapy was not as encouraging as the data for MSS mCRC cancer. We report the treatment of a series of patients with extrahepatic metastasis of MSS colorectal cancer, which can provide reference and guidance for the treatment of non-hepatic metastasis of MSS colorectal.Case presentationThis report describes 8 typical cases of successful MSS treatment with lung metastases of CRC. We systematically reviewed the clinical data and detailed medical history of one of these patients with extrahepatic metastasis from MSS colorectal cancer, and reviewed the literature to analyze and discuss the related epidemiological features, mechanisms and recent research findings of the special subgroup of the population.ConclusionsAlthough MSS colon rectal cancer is still known as a cold tumor in the industry, immunotherapy combined with multi-targeted anti-vascular tyrosine kinase inhibitors had brought clinical benefits to patients with non-hepatic metastases from MSS colorectal cancer. |
| first_indexed | 2024-04-10T04:33:39Z |
| format | Article |
| id | doaj.art-2de6d0b9f0854c1897b568358d14f4ac |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-10T04:33:39Z |
| publishDate | 2023-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-2de6d0b9f0854c1897b568358d14f4ac2023-03-10T05:27:20ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-03-011310.3389/fonc.2023.10916691091669Case Report: MSS colorectal extrahepatic (non-liver) metastases as the dominant population for immunotherapy combined with multi-target tyrosine kinase inhibitorsJiayin Liu0Dan Li1Jing Han2Yin Zhang3Xue Zhang4Zhisong Fan5Li Feng6Long Wang7Hui Jin8Jing Zuo9Yudong Wang10Department of Medical Oncology, The Fourth Hospital of Hebei Medical University and Hebei Provincial Tumor Hospital, Shijiazhuang, ChinaDepartment of Medical Oncology, The Fourth Hospital of Hebei Medical University and Hebei Provincial Tumor Hospital, Shijiazhuang, ChinaDepartment of Medical Oncology, The Fourth Hospital of Hebei Medical University and Hebei Provincial Tumor Hospital, Shijiazhuang, ChinaInspection Department, Shijiazhuang Institue for Food and Drug Control, Shijiazhuang, Hebei, ChinaDepartment of Medical Oncology, The Fourth Hospital of Hebei Medical University and Hebei Provincial Tumor Hospital, Shijiazhuang, ChinaDepartment of Medical Oncology, The Fourth Hospital of Hebei Medical University and Hebei Provincial Tumor Hospital, Shijiazhuang, ChinaDepartment of Medical Oncology, The Fourth Hospital of Hebei Medical University and Hebei Provincial Tumor Hospital, Shijiazhuang, ChinaDepartment of Medical Oncology, The Fourth Hospital of Hebei Medical University and Hebei Provincial Tumor Hospital, Shijiazhuang, ChinaDepartment of Medical Oncology, The Fourth Hospital of Hebei Medical University and Hebei Provincial Tumor Hospital, Shijiazhuang, ChinaDepartment of Medical Oncology, The Fourth Hospital of Hebei Medical University and Hebei Provincial Tumor Hospital, Shijiazhuang, ChinaDepartment of Medical Oncology, The Fourth Hospital of Hebei Medical University and Hebei Provincial Tumor Hospital, Shijiazhuang, ChinaBackgroundThe microsatellite stability(MSS) subtype of Colorectal Cancer(CRC) represents approximately 95% of mCRC cases. Immunotherapy was not as encouraging as the data for MSS mCRC cancer. We report the treatment of a series of patients with extrahepatic metastasis of MSS colorectal cancer, which can provide reference and guidance for the treatment of non-hepatic metastasis of MSS colorectal.Case presentationThis report describes 8 typical cases of successful MSS treatment with lung metastases of CRC. We systematically reviewed the clinical data and detailed medical history of one of these patients with extrahepatic metastasis from MSS colorectal cancer, and reviewed the literature to analyze and discuss the related epidemiological features, mechanisms and recent research findings of the special subgroup of the population.ConclusionsAlthough MSS colon rectal cancer is still known as a cold tumor in the industry, immunotherapy combined with multi-targeted anti-vascular tyrosine kinase inhibitors had brought clinical benefits to patients with non-hepatic metastases from MSS colorectal cancer.https://www.frontiersin.org/articles/10.3389/fonc.2023.1091669/fullMSSextrahepatic (non-liver) metastasesdominant populationimmunotherapy combinedmulti-target tyrosine kinase inhibitors |
| spellingShingle | Jiayin Liu Dan Li Jing Han Yin Zhang Xue Zhang Zhisong Fan Li Feng Long Wang Hui Jin Jing Zuo Yudong Wang Case Report: MSS colorectal extrahepatic (non-liver) metastases as the dominant population for immunotherapy combined with multi-target tyrosine kinase inhibitors Frontiers in Oncology MSS extrahepatic (non-liver) metastases dominant population immunotherapy combined multi-target tyrosine kinase inhibitors |
| title | Case Report: MSS colorectal extrahepatic (non-liver) metastases as the dominant population for immunotherapy combined with multi-target tyrosine kinase inhibitors |
| title_full | Case Report: MSS colorectal extrahepatic (non-liver) metastases as the dominant population for immunotherapy combined with multi-target tyrosine kinase inhibitors |
| title_fullStr | Case Report: MSS colorectal extrahepatic (non-liver) metastases as the dominant population for immunotherapy combined with multi-target tyrosine kinase inhibitors |
| title_full_unstemmed | Case Report: MSS colorectal extrahepatic (non-liver) metastases as the dominant population for immunotherapy combined with multi-target tyrosine kinase inhibitors |
| title_short | Case Report: MSS colorectal extrahepatic (non-liver) metastases as the dominant population for immunotherapy combined with multi-target tyrosine kinase inhibitors |
| title_sort | case report mss colorectal extrahepatic non liver metastases as the dominant population for immunotherapy combined with multi target tyrosine kinase inhibitors |
| topic | MSS extrahepatic (non-liver) metastases dominant population immunotherapy combined multi-target tyrosine kinase inhibitors |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1091669/full |
| work_keys_str_mv | AT jiayinliu casereportmsscolorectalextrahepaticnonlivermetastasesasthedominantpopulationforimmunotherapycombinedwithmultitargettyrosinekinaseinhibitors AT danli casereportmsscolorectalextrahepaticnonlivermetastasesasthedominantpopulationforimmunotherapycombinedwithmultitargettyrosinekinaseinhibitors AT jinghan casereportmsscolorectalextrahepaticnonlivermetastasesasthedominantpopulationforimmunotherapycombinedwithmultitargettyrosinekinaseinhibitors AT yinzhang casereportmsscolorectalextrahepaticnonlivermetastasesasthedominantpopulationforimmunotherapycombinedwithmultitargettyrosinekinaseinhibitors AT xuezhang casereportmsscolorectalextrahepaticnonlivermetastasesasthedominantpopulationforimmunotherapycombinedwithmultitargettyrosinekinaseinhibitors AT zhisongfan casereportmsscolorectalextrahepaticnonlivermetastasesasthedominantpopulationforimmunotherapycombinedwithmultitargettyrosinekinaseinhibitors AT lifeng casereportmsscolorectalextrahepaticnonlivermetastasesasthedominantpopulationforimmunotherapycombinedwithmultitargettyrosinekinaseinhibitors AT longwang casereportmsscolorectalextrahepaticnonlivermetastasesasthedominantpopulationforimmunotherapycombinedwithmultitargettyrosinekinaseinhibitors AT huijin casereportmsscolorectalextrahepaticnonlivermetastasesasthedominantpopulationforimmunotherapycombinedwithmultitargettyrosinekinaseinhibitors AT jingzuo casereportmsscolorectalextrahepaticnonlivermetastasesasthedominantpopulationforimmunotherapycombinedwithmultitargettyrosinekinaseinhibitors AT yudongwang casereportmsscolorectalextrahepaticnonlivermetastasesasthedominantpopulationforimmunotherapycombinedwithmultitargettyrosinekinaseinhibitors |